Pancreatic Cancer Research

ResearcherBrentwood Biomedical Research InstituteActive in the last 2 years

Aurelia Lugea

Matched on OpenAlex author ID A5061294594; NIH RePORTER profile ID 7983301. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 1)
Trials
0
Grants
1
Labs led
2
Collaborators
33
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 1 grant · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 10

  1. Selective removal of proteins and microvesicles ex vivo from blood of pancreatic cancer patients using bioengineered adsorption filters. Co-author DOI 10.1016/j.canlet.2025.217546↗
  2. Upregulated Matrisomal Proteins and Extracellular Matrix Mechanosignaling Underlie Obesity-Associated Promotion of Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers16081593↗
  3. Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. Co-author DOI 10.1038/s41598-023-43498-9↗
  4. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. Co-author DOI 10.1016/j.jand.2017.07.005↗
  5. Exosome-Mediated Intercellular Communication Between Stellate Cells and Cancer Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000686↗
  6. Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. Co-author DOI 10.1371/journal.pone.0184455↗
  7. Diabetes, pancreatic cancer, and metformin therapy. Co-author DOI 10.3389/fphys.2014.00426↗
  8. A starring role for stellate cells in the pancreatic cancer microenvironment. Co-author DOI 10.1053/j.gastro.2012.11.037↗
  9. Ellagic acid and embelin affect key cellular components of pancreatic adenocarcinoma, cancer, and stellate cells. First author DOI 10.1080/01635581.2013.832779↗
  10. Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. Last author DOI 10.1111/j.1440-1746.2011.07013.x↗

Grants 1

  1. Alcohol abuse and Endoplasmic Reticulum dysfunction in exocrine pancreas R01AA019954↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stephen Jacob Pandol · 9 shared papers, 2012–2025 · strength 0.91
  2. Richard T. Waldron · 6 shared papers, 2014–2025 · strength 0.86
  3. Guido Eibl · 6 shared papers, 2012–2024 · strength 0.58
  4. Enrique Rozengurt · 3 shared papers, 2017–2024 · strength 0.43
  5. Hui-Hua Chang · 2 shared papers, 2017–2024 · strength 0.25
  6. James W. Sinnett‐Smith · 2 shared papers, 2017–2023 · strength 0.23
  7. Oscar Joe Hines · 2 shared papers, 2017–2023 · strength 0.23
  8. Simon K. Lo · 1 shared paper, 2025 · strength 0.23
  9. Stephanie N. Shishido · 1 shared paper, 2025 · strength 0.23
  10. Ruoxiang Wang · 1 shared paper, 2025 · strength 0.23
  11. Peter Kühn · 1 shared paper, 2025 · strength 0.23
  12. Yaroslav Teper · 1 shared paper, 2023 · strength 0.18
  13. Linda Ye · 1 shared paper, 2023 · strength 0.18
  14. Xiaoying Sun · 1 shared paper, 2023 · strength 0.18
  15. Anna S. Gukovskaya · 2 shared papers, 2012–2017 · strength 0.09
  16. David W. Dawson · 2 shared papers, 2012–2017 · strength 0.09
  17. Mark Goodarzi · 1 shared paper, 2018 · strength 0.08
  18. William E. Fisher · 1 shared paper, 2018 · strength 0.08
  19. Aida Habtezion · 1 shared paper, 2018 · strength 0.08
  20. Murray Korc · 1 shared paper, 2018 · strength 0.08
  21. Dana K. Andersen · 1 shared paper, 2018 · strength 0.08
  22. Zobeida Cruz‐Monserrate · 1 shared paper, 2018 · strength 0.08
  23. Maxim S. Petrov · 1 shared paper, 2018 · strength 0.08
  24. Phil A. Hart · 1 shared paper, 2018 · strength 0.08
  25. Mouad Edderkaoui · 2 shared papers, 2012–2013 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.